JP2023548467A5 - - Google Patents

Info

Publication number
JP2023548467A5
JP2023548467A5 JP2023526068A JP2023526068A JP2023548467A5 JP 2023548467 A5 JP2023548467 A5 JP 2023548467A5 JP 2023526068 A JP2023526068 A JP 2023526068A JP 2023526068 A JP2023526068 A JP 2023526068A JP 2023548467 A5 JP2023548467 A5 JP 2023548467A5
Authority
JP
Japan
Prior art keywords
cells
cell
receptor
car
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058118 external-priority patent/WO2022098914A1/en
Publication of JP2023548467A publication Critical patent/JP2023548467A/ja
Publication of JP2023548467A5 publication Critical patent/JP2023548467A5/ja
Pending legal-status Critical Current

Links

JP2023526068A 2020-11-04 2021-11-04 操作されたiPSC及び持続性免疫エフェクター細胞 Pending JP2023548467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063109828P 2020-11-04 2020-11-04
US63/109,828 2020-11-04
PCT/US2021/058118 WO2022098914A1 (en) 2020-11-04 2021-11-04 Engineered ipsc and persistent immune effector cells

Publications (2)

Publication Number Publication Date
JP2023548467A JP2023548467A (ja) 2023-11-17
JP2023548467A5 true JP2023548467A5 (cg-RX-API-DMAC10.html) 2024-11-13

Family

ID=81457363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526068A Pending JP2023548467A (ja) 2020-11-04 2021-11-04 操作されたiPSC及び持続性免疫エフェクター細胞

Country Status (10)

Country Link
US (1) US20230390337A1 (cg-RX-API-DMAC10.html)
EP (1) EP4240831A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023548467A (cg-RX-API-DMAC10.html)
KR (1) KR20230098649A (cg-RX-API-DMAC10.html)
CN (1) CN116406373A (cg-RX-API-DMAC10.html)
AU (1) AU2021372975A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196545A1 (cg-RX-API-DMAC10.html)
IL (1) IL302471A (cg-RX-API-DMAC10.html)
MX (1) MX2023005029A (cg-RX-API-DMAC10.html)
WO (1) WO2022098914A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
CN116716342A (zh) * 2022-06-22 2023-09-08 南京艾尔普再生医学科技有限公司 一种adcc功能增强的nk细胞的制作方法、nk细胞及其组合物
JP2025522824A (ja) * 2022-07-01 2025-07-17 フェイト セラピューティクス,インコーポレイティド 養子細胞療法におけるエフェクター細胞の耐久性及び有効性の増強
AU2023315762A1 (en) * 2022-07-25 2025-01-30 Immunitybio, Inc. Treatment of mhc-i negative tumors with nk and t cells
WO2024097800A1 (en) * 2022-11-01 2024-05-10 Fate Therapeutics, Inc. Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2
WO2024097901A1 (en) * 2022-11-02 2024-05-10 Fate Therapeutics, Inc. Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b
WO2025064822A2 (en) * 2023-09-20 2025-03-27 Factor Bioscience Inc. Cells and methods for engineering cells with persistent transgene expression
CN118909951B (zh) * 2024-07-05 2025-05-13 青岛华赛伯曼医学细胞生物有限公司 连续杀伤能力增强的工程化til细胞及其应用
WO2026025087A1 (en) * 2024-07-26 2026-01-29 Dana-Farber Cancer Institute, Inc. Nucleic acids and engineered cells for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
EP3774866A1 (en) * 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
JP2022510207A (ja) * 2018-12-02 2022-01-26 フェイト セラピューティクス,インコーポレイテッド 増強されたiPSC派生エフェクター細胞を使用した免疫療法
CN113906133A (zh) * 2019-04-11 2022-01-07 菲特治疗公司 工程改造的iPSC和免疫效应细胞中的CD3重建
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2022541441A5 (cg-RX-API-DMAC10.html)
JP2022550899A5 (cg-RX-API-DMAC10.html)
JP2022548943A5 (cg-RX-API-DMAC10.html)
JP2021505131A5 (cg-RX-API-DMAC10.html)
AU2021201679B2 (en) Transgene genetic tags and methods of use
JP2023549098A5 (cg-RX-API-DMAC10.html)
JP2022510207A5 (cg-RX-API-DMAC10.html)
JP2023548829A5 (cg-RX-API-DMAC10.html)
JP2023505206A5 (cg-RX-API-DMAC10.html)
JP2021519061A5 (cg-RX-API-DMAC10.html)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
JP2023530704A5 (cg-RX-API-DMAC10.html)
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
JP2023545992A5 (cg-RX-API-DMAC10.html)
JP2024109827A (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
KR20210126008A (ko) 세포 면역 치료의 조합
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
KR20210018838A (ko) 유전자 조작된 세포 및 응용
IL294518A (en) Bcma-directed cellular immunotherapy compositions and methods
JP2024515920A5 (cg-RX-API-DMAC10.html)
JP2025520124A (ja) キメラアダプターポリペプチドを含む組成物及び方法
JP2024526237A5 (cg-RX-API-DMAC10.html)